Homepage Top Section1

As part of single target research collaboration, both companies will conduct research activities to select a pre-clinical candidate after which Roche will focus on further development and global

The interim analysis showed that Sputnik V vaccine has shown an efficacy rate of 92% after the second dose in the patients. Sputnik V vaccine is based on

The EUA status enables to use bamlanivimab 700 mg to treat mild to moderate Covid-19 in adults and paediatric patients aged 12 years and older with a positive

Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101, the company’s investigational antibody-drug conjugate

Clover will use the funding to conduct the global pivotal phase 2/3 efficacy clinical trial of the protein-based S-Trimer Covid-19 vaccine candidate. It will also use the funds

Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to

The multicentre trial has been designed to assess the safety and efficacy of oral niclosamide formulation to treat patients with moderate Covid-19 disease. The study is said to

Veklury is now the first treatment to have been approved by the FDA for Covid-19. It has been approved to be used in adult as well as paediatric

Branaplam has been demonstrated to decrease levels of mutant huntingtin protein in preclinical models, said Novartis. Based on the results, Novartis aims to begin a development programme for